ASCENIV prescription volume growth and market share gains in the PIDD segment (estimated 15,000 PIDD patients in US, growing 3-5% annually)
Plasma collection center expansion and donor recruitment metrics (each center can generate $8-12M annual plasma value at maturity)
Manufacturing yield improvements and cost per gram reductions at Boca Raton facility (targeting sub-$40 COGS per gram)
Regulatory developments including potential label expansions or competitive approvals in IVIG market
low - PIDD is a chronic, life-threatening condition requiring continuous immunoglobulin replacement therapy regardless of economic conditions. Patient demand is non-discretionary and largely insulated from GDP fluctuations. However, plasma donor recruitment can be moderately sensitive to employment conditions—higher unemployment may increase donor availability as individuals seek supplemental income ($50-75 per donation). Hospital purchasing patterns show minimal cyclicality as IVIG is essential formulary item.
Rising interest rates have minimal direct operational impact given ADMA's low debt load (0.19 D/E ratio) and positive operating cash flow. However, higher rates compress valuation multiples for high-growth biotech stocks, as investors demand higher discount rates for future earnings. The 7.7x P/S ratio is vulnerable to multiple compression if 10-year Treasury yields rise significantly above 4.5%. Financing costs for potential M&A or capacity expansion would increase modestly, but unlikely to materially impact strategy given strong balance sheet (7.13 current ratio).
Regulatory risk from FDA manufacturing inspections and potential consent decrees affecting plasma fractionation operations (industry has history of compliance issues leading to supply disruptions)
Reimbursement pressure from payers seeking to shift PIDD patients to subcutaneous immunoglobulin (SCIG) products or biosimilars, potentially compressing IVIG pricing over 3-5 year horizon
Plasma supply constraints if donor recruitment slows or competing fractionators expand collection capacity, driving up per-liter acquisition costs
growth - The 65% revenue growth, 800% net income growth, and 54% ROE attract growth investors seeking high-margin biotech scalability stories. The stock appeals to healthcare specialists focused on commercial-stage biopharma with proven products and clear paths to profitability. Momentum investors have rotated in/out based on quarterly results, evidenced by volatile 6-month performance. Limited institutional ownership (estimated 60-70%) suggests room for discovery by larger growth funds. Not suitable for income investors (no dividend) or deep value players (7.7x P/S is premium to biotech median).
Trend
-35.4% vs SMA 50 · -48.2% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $510.6M $482.1M–$546.5M | — | $0.58 | — | ±8% | Low1 |
FY2026(current) | $570.1M $538.3M–$610.2M | ▲ +11.6% | $0.84 | ▲ +44.2% | ±4% | Low2 |
FY2027 | $689.4M $650.9M–$737.9M | ▲ +20.9% | $1.08 | ▲ +28.1% | ±8% | Moderate3 |
INSTITUTIONAL OWNERSHIP
ADMA News
About
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
ADMA◀ | $8.27 | -2.71% | $1.9B | 11.8 | +1963.1% | 2880.0% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.93% | — | 31.1 | +342130.3% | -3090.5% | 1500 |